Snipr Biome shows proof of principle in phase I trial of lead asset
The CRISPR company presents positive interim data from an early-stage study of a drug that can reduce E.coli levels in the gut.
by albert rønning-andersson, translated by daniel pedersen
Copenhagen-based CRISPR company Snipr Biome has demonstrated proof of principle – that lead asset SNIPR001 can reduce E.coli levels in the human gastrointestinal tract.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Win-win or naivete? – Snipr Biome to spill its secrets
For subscribers
Snipr secures important US patent
For subscribers
Snipr Biome fights to regain five US patents
For subscribers
